Walter Klemp Files Initial 13D on Autonomix Medical, Inc.

TL;DR

**Insider Walter Klemp just disclosed a significant stake in Autonomix Medical (AMIX) via a new 13D filing!**

AI Summary

Walter V Klemp filed an initial Schedule 13D on February 15, 2024, disclosing an event on January 26, 2024, regarding his beneficial ownership in Autonomix Medical, Inc. This filing indicates Klemp has acquired more than 5% of the company's Common Stock, signaling a significant stake. The specific percentage or dollar amount of his holding is not detailed in this initial snippet, but it establishes his position as a major shareholder.

Why It Matters

A Schedule 13D filing signals a significant ownership stake (over 5%) by an individual or group, often indicating an activist investor or a substantial insider position, which can influence company strategy or investor sentiment.

Risk Assessment

Risk Level: medium — The filing indicates a significant ownership position by an individual associated with the company, which could lead to either supportive or activist actions, creating potential for future changes.

Key Numbers

• 5% — Ownership Threshold (Minimum ownership percentage requiring a Schedule 13D filing)

Key Players & Entities

• Walter V Klemp (person) — Filer of SC 13D
• Autonomix Medical, Inc. (company) — Subject Company
• January 26, 2024 (date) — Date of Event Which Requires Filing
• February 15, 2024 (date) — Filing Date
• 05330T 106 (other) — CUSIP Number for Common Stock

FAQ

Key Financial Figures

• $0.001 — o the shares of common stock, par value $0.001 per share (the “Common Stock&rdqu
• $200,000 — e Reporting Person annual board fees of $200,000 per year. In connection with the Report
• $2.00 — of common stock at a purchase price of $2.00 per share. In connection with such priv
• $1.00 — common stock, with an exercise price of $1.00 per share. The Reporting Person acquire
• $100,000 — er share. The Reporting Person acquired $100,000 in principal amount of the convertible

Filing Documents

• klemp_sc13d.htm (SC 13D) — 41KB
• 0001683168-24-001033.txt ( ) — 43KB

below summarizes the agreements pursuant

Item 4 below summarizes the agreements pursuant to which the securities beneficially owned by the Reporting Person were acquired. Item 4. Purpose of Transaction. In January 2022, the Issuer entered into a director offer letter with the Reporting Person to serve as its Executive Chairman. Pursuant to the letter, the Issuer agreed to pay the Reporting Person annual board fees of $200,000 per year. In connection with the Reporting Person’s appointment to the Board, the Issuer issued the Reporting Person a stock grant of 2,890,000 shares of common stock. In March 2023, the Issuer completed a private placement of common stock at a purchase price of $2.00 per share. In connection with such private placement, the Reporting Person purchased 50,000 shares of common stock. In September 2023, the Issuer commenced a private placement of convertible notes with a maturity date of December 31, 2025. For each dollar in principal amount of convertible notes purchased, the Issuer issued a warrant to purchase 0.25 shares of its common stock, with an exercise price of $1.00 per share. The Reporting Person acquired $100,000 in principal amount of the convertible notes and received a warrant to purchase 25,000 shares of common stock. Upon the listing of the Issuer’s common stock on a national securities exchange, the principal amount of the convertible notes converted into 50,000 shares of Issuer common stock at a conversion price of $2.00 per share. The purchasers of the convertible notes agreed for a period of six months after the listing of the Issuer common stock on a national securities exchange, to lock-up the shares of common stock underlying the convertible notes and warrants, and thereafter the foregoing lock-up will cease to apply to 1/4th of the shares of common stock underlying the convertible notes and warrants each month for a period of four months. In connection with the Issuer’s initial public offering, the Reporting Person entered into a lock-up

above summarizes certain provisions of the

Item 4 above summarizes certain provisions of the Registration Rights Agreement and the Lock-Up Agreements, and is incorporated herein by reference. A copy of each such agreement is attached as an exhibit to this Schedule 13D, and is incorporated herein by reference. The Reporting Person does not have any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies. CUSIP No. 05330T 106 13D Page 4 of 5 pages Item 7. Materials to be Filed as Exhibits. Exhibit Number Description 1 Form of Lock-Up Agreement (incorporated by reference to Exhibit 6.7 of the Issuer’s Form 1-A POS filed number 024-12296 filed on January 19, 2024). 5 CUSIP No. 05330T 106 13D Page 5 of 5 pages

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : February 15, 2024 By: /s/ Walter V. Klemp Name: Walter V. Klemp

View Full Filing

View this SC 13D filing on SEC EDGAR